|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: H2AFZ |
Gene summary for H2AFZ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | H2AFZ | Gene ID | 3015 |
| Gene name | H2A.Z variant histone 1 | |
| Gene Alias | H2A.Z-1 | |
| Cytomap | 4q23 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P0C0S5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3015 | H2AFZ | GSM5276935 | Human | Endometrium | EEC | 3.32e-06 | 2.75e-01 | -0.123 |
| 3015 | H2AFZ | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.59e-25 | -2.43e-01 | -0.1869 |
| 3015 | H2AFZ | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 7.11e-33 | -2.51e-01 | -0.1875 |
| 3015 | H2AFZ | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.91e-33 | -2.06e-01 | -0.1883 |
| 3015 | H2AFZ | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.56e-31 | -2.31e-01 | -0.1934 |
| 3015 | H2AFZ | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 5.83e-42 | -2.34e-01 | -0.1917 |
| 3015 | H2AFZ | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.26e-45 | -2.58e-01 | -0.1916 |
| 3015 | H2AFZ | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 5.00e-06 | 1.26e-01 | -0.1269 |
| 3015 | H2AFZ | LZE2T | Human | Esophagus | ESCC | 6.47e-15 | 2.57e+00 | 0.082 |
| 3015 | H2AFZ | LZE4T | Human | Esophagus | ESCC | 1.52e-15 | 1.42e+00 | 0.0811 |
| 3015 | H2AFZ | LZE5T | Human | Esophagus | ESCC | 3.47e-02 | 1.03e+00 | 0.0514 |
| 3015 | H2AFZ | LZE7T | Human | Esophagus | ESCC | 9.86e-14 | 1.93e+00 | 0.0667 |
| 3015 | H2AFZ | LZE8T | Human | Esophagus | ESCC | 1.14e-09 | 1.65e+00 | 0.067 |
| 3015 | H2AFZ | LZE20T | Human | Esophagus | ESCC | 3.76e-07 | 8.31e-01 | 0.0662 |
| 3015 | H2AFZ | LZE22D1 | Human | Esophagus | HGIN | 3.05e-03 | 8.43e-01 | 0.0595 |
| 3015 | H2AFZ | LZE22T | Human | Esophagus | ESCC | 2.33e-05 | 2.00e+00 | 0.068 |
| 3015 | H2AFZ | LZE24T | Human | Esophagus | ESCC | 1.18e-22 | 1.98e+00 | 0.0596 |
| 3015 | H2AFZ | LZE21T | Human | Esophagus | ESCC | 3.67e-09 | 1.85e+00 | 0.0655 |
| 3015 | H2AFZ | LZE6T | Human | Esophagus | ESCC | 4.73e-18 | 1.91e+00 | 0.0845 |
| 3015 | H2AFZ | P1T-E | Human | Esophagus | ESCC | 1.60e-14 | 1.86e+00 | 0.0875 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05322 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa053221 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| H2AFZ | SNV | Missense_Mutation | c.241N>T | p.Arg81Cys | p.R81C | P0C0S5 | protein_coding | deleterious(0.03) | benign(0.025) | TCGA-A1-A0SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |
| H2AFZ | SNV | Missense_Mutation | c.241C>T | p.Arg81Cys | p.R81C | P0C0S5 | protein_coding | deleterious(0.03) | benign(0.025) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| H2AFZ | SNV | Missense_Mutation | c.24N>C | p.Lys8Asn | p.K8N | P0C0S5 | protein_coding | deleterious(0.03) | possibly_damaging(0.771) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| H2AFZ | SNV | Missense_Mutation | c.116N>A | p.Ser39Tyr | p.S39Y | P0C0S5 | protein_coding | deleterious(0) | benign(0.275) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| H2AFZ | SNV | Missense_Mutation | c.127N>T | p.Ser43Cys | p.S43C | P0C0S5 | protein_coding | deleterious(0.03) | probably_damaging(0.962) | TCGA-DY-A1DF-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| H2AFZ | SNV | Missense_Mutation | novel | c.296N>A | p.Ser99Tyr | p.S99Y | P0C0S5 | protein_coding | deleterious(0) | possibly_damaging(0.675) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| H2AFZ | SNV | Missense_Mutation | novel | c.128N>T | p.Ser43Ile | p.S43I | P0C0S5 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| H2AFZ | SNV | Missense_Mutation | c.217G>A | p.Ala73Thr | p.A73T | P0C0S5 | protein_coding | deleterious(0.02) | possibly_damaging(0.577) | TCGA-BS-A0TE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| H2AFZ | SNV | Missense_Mutation | c.314N>G | p.Ile105Ser | p.I105S | P0C0S5 | protein_coding | deleterious(0) | benign(0.315) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| H2AFZ | SNV | Missense_Mutation | c.325N>T | p.Gly109Cys | p.G109C | P0C0S5 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-D1-A17B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |